Inherit

Octapharma USA: FDA Grants Orphan Drug Exclusivity to wilate®, the First VWF Concentrate for Prophylaxis in All Types of VWD

Retrieved on: 
Monday, April 29, 2024
FDA, Haemophilia, Patient, Bleeding, News, Hospital, Food, Therapy, Von Willebrand disease, Disease, Caregiver, Thrombosis, Health, Coagulopathy, The O'Reilly Factor, VWD, Inherit, Quality of life, VWF, Pharmaceutical industry

Patients with severe VWD are recommended to utilize long-term prophylaxis with VWF concentrate.

Key Points: 
  • Patients with severe VWD are recommended to utilize long-term prophylaxis with VWF concentrate.
  • The FDA Orphan Drug Designation program provides orphan status to biologics and drugs for rare diseases.
  • "The FDA orphan exclusivity is exciting news for Octapharma and patients who have endured excessive bleeding episodes," said Octapharma USA President Flemming Nielsen.
  • The Factor My Way patient support program is designed by Octapharma USA for those living with VWD and hemophilia A.

Molecular Diagnostics in Oncology, Genetic/Inherited Diseases and NIPT 2023-2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 29, 2024
Health, Oncology, ISH, NGS, DSM-IV codes, Research, Molecular diagnostics, IVD, Knowledge, NIPT, Cancer, Woman, Medicine, Risk, FISH, Recurrence, Laboratory, FDA, Biomarker, Diagnosis, PCR, Inherit, Segment, Chromosome, Gene expression, Medical imaging

The "Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Molecular Diagnostics in Oncology, Genetic/Inherited Diseases, and NIPT, 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • In addition, the fields of rare inherited/ genetic diseases and NIPT have become areas of new breakthroughs in healthcare.
  • These and other technologies and applications in oncology, rare inherited/ genetic disease, and NIPT molecular diagnostic testing are covered in the report.
  • The report contains detailed market data on the following IVD segments for their use in molecular testing:
    Molecular Diagnostics in Oncology Market by Segment, 2023-2028

Ceva and Actions Technology Commemorate Landmark Achievement, Surpassing 100 Million Ceva-Powered Wireless Audio and AIoT Processors Shipped

Retrieved on: 
Wednesday, January 10, 2024
Vizio, Socs, Silicon, Razer, Boat, IP, LAS, Sony, DSP, Artificial intelligence, SOC, IC, Noise, AI, CEVA, TCL, Original equipment manufacturer, Human, Actions Semiconductor, IPS, Inherit, Mobile phone

LAS VEGAS, Jan. 10, 2024 /PRNewswire/ -- CES 2024 -- Ceva, Inc. (NASDAQ: CEVA), the leading licensor of silicon and software IP that enables Smart Edge devices to connect, sense and infer data more reliably and efficiently, and Actions Technology Co, Ltd. ("Actions Space Technology"), the leading fabless semiconductor company of AIoT (Artificial Intelligence of Things) SoC, are celebrating a monumental achievement today, with Actions surpassing sales of more than 100 million wireless audio and AIoT chips powered by Ceva's audio, voice, AI sensing and wireless communications IPs.

Key Points: 
  • Actions Technology produces AIoT SoCs which power wireless audio, portable audio-visual, and edge AI processor applications.
  • Ceva and Actions Technology have collaborated closely in the fields of DSP and AI processing in the audio field and related wireless workloads.
  • Zhenyu Zhou, Chairman & CEO of Actions Technology, stated: "For the past decade, Actions Technology has been at the forefront of wireless audio innovation, thanks to our deep understanding of these technologies and our joint work with Ceva.
  • Surpassing 100 million Ceva-powered wireless audio chipsets shipped is an incredible achievement for our companies.

MiNA Therapeutics Highlights Preclinical Research on RNA Activation (RNAa) Therapeutics Presented at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

Retrieved on: 
Wednesday, October 25, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Mina, OTS, Acute myeloid leukemia, Therapy, RNA, Bone marrow, Cell, RNAa, Inherit, Gene, Oligonucleotide, AML, Regulation, Vaccine

MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, highlights preclinical research presented by academic partners at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.

Key Points: 
  • MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, highlights preclinical research presented by academic partners at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.
  • RNAa therapeutics are a revolutionary new class of medicines that can restore or boost normal function of genes and thereby protein-modulated pathways in cells.
  • Another study titled, “Small-Activating RNA Therapy Development for the Inherited genetic Disorder Aniridia,” revealed the potential of RNAa therapeutics to treat a rare and severe genetic eye disease.
  • “The findings from these three preclinical studies demonstrate continued advances in the development of our novel RNAa therapeutics across a range of therapeutic areas,” said Robert Habib, CEO of MiNA Therapeutics.

Global and Regional Rare Disease Genetic Testing Market Analysis & Forecasts Report 2023-2033 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 9, 2023
Health, Genetics, Diagnosis, Incidence, Parent, Hospital, DSM-IV codes, Physician, Exome, Plasma, Research, SRL Diagnostics, Genome, Prevalence, PCR, BGI Group, NGS, DNA, CVS, Risk, SNV calling from NGS data, Sanger, Massive parallel sequencing, Metabolism, Amniocentesis, Genetic code, Disease, State Key Laboratories, R, Inherit, Genomics, Patient, Polymerase chain reaction, WES, WGS, Genetic counseling, Growth, Genetic testing, Region, National Centre for Foreign Animal Disease, Gene, Rare, Chromosome, Fetus, Cardiogenic shock, Serum, Birth, Gastroenterology, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Dietary supplement

The "Rare Disease Genetic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Offering, Specialty Type, Sample Type, Trait Type, Technology, Age Group, End User, and Country Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rare Disease Genetic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Offering, Specialty Type, Sample Type, Trait Type, Technology, Age Group, End User, and Country Analysis - Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
  • The global market for rare disease genetic testing encompasses an array of panels and tests that excel in detecting rare diseases.
  • The global rare disease genetic testing market has experienced remarkable growth, driven by the escalating demand for early detection of rare diseases.
  • Moreover, a maximum number of rare disease testing is done there, due to which these regions hold the maximum share in the global rare disease genetic testing market.

Global and Regional Rare Disease Genetic Testing Market Report 2023-2033: Early Detection Demand and Innovative Systems Usher in New Era for Rare Disease Genetic Testing

Retrieved on: 
Tuesday, October 3, 2023
Chromosome, DNA, Sanger, National Centre for Foreign Animal Disease, Gastroenterology, Prevalence, BGI Group, DSM-IV codes, Serum, Disease, Fetus, Genomics, Parent, Hospital, Cardiogenic shock, SRL Diagnostics, NGS, Amniocentesis, CVS, Genetic testing, Research, Birth, Genetic code, Exome, Incidence, Genetic counseling, Plasma, Metabolism, Patient, Polymerase chain reaction, Physician, Risk, State Key Laboratories, WGS, Inherit, Growth, Diagnosis, Region, R, Rare, WES, SNV calling from NGS data, Massive parallel sequencing, Gene, PCR, Genome, Pharmaceutical industry, Medical imaging, Vaccine, Medical device, Dietary supplement

The global market for rare disease genetic testing encompasses an array of panels and tests that excel in detecting rare diseases.

Key Points: 
  • The global market for rare disease genetic testing encompasses an array of panels and tests that excel in detecting rare diseases.
  • Among the most prevalent rare disease genetic testing panels are those tailored for gastroenterology, endocrine and metabolic disorders, and neurological diseases.
  • The global rare disease genetic testing market has experienced remarkable growth, driven by the escalating demand for early detection of rare diseases.
  • Moreover, a maximum number of rare disease testing is done there, due to which these regions hold the maximum share in the global rare disease genetic testing market.

Inherited Podcast Centers Youth Stories on the Devastating Impact of Wildfires, Climate Resilience in Indigenous Communities, the Lasting Effects of Hurricane Maria, and More in Season 3

Retrieved on: 
Wednesday, July 19, 2023
Tao, Hurricane Maria, Critical frequency, Agriculture, Policy, Movement, Season, CO, Climate change, Youth Radio, Apple Podcasts, Google Podcasts, Nature, Pasifika, Amazon Music, TuneIn, Family, Social media, Mad Men (season 3), Entertainment, Animal husbandry, Spotify, Stitcher, Inherit

Oakland, CA, July 19, 2023 (GLOBE NEWSWIRE) -- Inherited , the critically acclaimed youth climate movement storytelling podcast, is back for Season 3.

Key Points: 
  • Oakland, CA, July 19, 2023 (GLOBE NEWSWIRE) -- Inherited , the critically acclaimed youth climate movement storytelling podcast, is back for Season 3.
  • Produced by YR Media and distributed by Critical Frequency , Inherited explores personal stories from young people all over the world who are grappling with the effects of climate change.
  • (Lagos, Nigeria)
    “Emma”: Emma Schulman, 19, explores the effects of climate-fueled wildfires in Colorado on already-susceptible domestic violence survivors.
  • Learn more about the podcast here and follow along on social media:

ORIEN Member Presentations at 2023 ASCO Demonstrate Unique Value of Aster Insights' Data

Retrieved on: 
Tuesday, May 30, 2023
Roswell Park Comprehensive Cancer Center, Focused Ultrasound Foundation, Partnership, Doctor of Pharmacy, University, CRC, Aster, American Society of Clinical Oncology, Cancer, Development of the human body, Research, Roswell Park, RNA, Immunotherapy, Doctor of Philosophy, AVATAR, ASCO, DO, Patient, Data, Sequence, Annual general meeting, Inherit, Genetic heterogeneity, Listeria monocytogenes non-coding RNA, H. Lee Moffitt Cancer Center & Research Institute, WES, Health, Society, Compugen (company), WTS, Pharmaceutical industry, Medical imaging, Vaccine

TAMPA, Fla., May 30, 2023 /PRNewswire/ -- Aster Insights ("the Company"), the leading provider of technology-enabled data and analytics solutions for oncology discovery, today announced its participation as a research partner at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, 2023 in Chicago, IL. An oral presentation and three posters will be presented at this year's ASCO meeting, utilizing the lifetime patient-consented longitudinal clinicogenomic data from the Company's Oncology Research Information Exchange Network® (ORIEN) AVATAR program. These presentations highlight the research partnerships and collaboration of Aster Insights and 18 premier cancer centers that comprise ORIEN.

Key Points: 
  • An oral presentation and three posters will be presented at this year's ASCO meeting, utilizing the lifetime patient-consented longitudinal clinicogenomic data from the Company's Oncology Research Information Exchange Network® ( ORIEN ) AVATAR program.
  • These presentations highlight the research partnerships and collaboration of Aster Insights and 18 premier cancer centers that comprise ORIEN.
  • "We are thrilled to be selected for these diverse presentations at ASCO that showcase the incredible work of ORIEN and Aster Insights," said Jill Kolesar, PharmD, Director of the Precision Medicine Center at the Markey Cancer Center and Chair of the ORIEN Executive Advisory Committee.
  • For more information about our ASCO presentations, please contact Aster Insights at: [email protected]

World Molecular Diagnostics Tests Market Report 2022: Next-Generation Sequencing on the Rise

Retrieved on: 
Monday, January 16, 2023
Hepatitis, Market, COVID-19, HIV, Single-nucleotide polymorphism, STI, NIPT, Medical device, Pharmaceutical industry, Vaccine, Animal, Inherit

DUBLIN, Jan. 16, 2023 /PRNewswire/ -- The "The World Market for Molecular Diagnostics Tests, 11th Edition" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 16, 2023 /PRNewswire/ -- The "The World Market for Molecular Diagnostics Tests, 11th Edition" report has been added to ResearchAndMarkets.com's offering.
  • In this report, our industry experts and top analysts assess the current positions of this complex market, which has an estimated value of more than $21 billion.
  • The report provides marketing sizing and forecasts for in vitro diagnostics (IVDs) over a five-year period.
  • Molecular Diagnostics Market (w COVID-19 and w/out COVID-19, 2021 ($B)
    Hundreds of PCR Tests on the Market, U.S. Labs Settle on a Few
    Estimated COVID-19 Molecular Diagnostic Revenue, Q1 2020-Q1 2021 COVID-19 Market

The World Market for Molecular Diagnostics Tests, 11th Edition - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 14, 2022
Health, Other Health, STI, HIV, Hepatitis, Single-nucleotide polymorphism, COVID-19, NIPT, Medical device, Vaccine, Pharmaceutical industry, Inherit

The "The World Market for Molecular Diagnostics Tests, 11th Edition" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The World Market for Molecular Diagnostics Tests, 11th Edition" report has been added to ResearchAndMarkets.com's offering.
  • The 11th Edition report of the clinical molecular testing industry provides marketing sizing and forecasts for in vitro diagnostics (IVDs) over a five-year period.
  • In this report, our industry experts and top analysts assess the current positions of this complex market, which has an estimated value of more than $21 billion.
  • This data publication has become an indispensable tool in clinical healthcare medicine and assesses the business opportunity, new product introductions, and rapid changes in several areas of this industry, including:
    Infectious Disease Molecular Diagnostics (COVID-19, Hepatitis, HIV, Respiratory, STI, Others)
    Genetic Molecular Diagnostic Markets (SNPs, Inherited, NIPT, Other)
    Regional Molecular Diagnostics Markets (North America, Europe, Asia, Global)
    Molecular diagnostics proved their value during the COVID-19 pandemic, but the heavily competitive market in 2022 demonstrates that market leaders need to anticipate quick and rapid changes.